Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus multimodality radiotherapy for advanced metastatic hepatocellular carcinoma after prior treatment failure
ChiCTR2100045674Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045674.